Basic Information
PharmNoah Intelligence is an innovative pharmaceutical company focusing on "undruggable targets." With protein-protein interaction (PPI) as the core entry point, the company deeply integrates cutting-edge AI technology to precisely identify novel druggable sites and efficiently advance the discovery and development of First-in-Class and Best-in-Class drugs. Targeting major disease areas such as autoimmune disorders and cancer, PharmNoah Intelligence has established a full-chain drug design system that starts with PPI and ends with druggability. Strategically, we prioritize key targets where "disrupting protein interactions" is the optimal solution. Technically, supported by an exclusive high-quality database and innovative algorithms, the team not only achieves intelligent molecule generation but also significantly enhances the prediction accuracy of complex druggability. This underlying technological closed-loop effectively overcomes individual high-difficulty targets and rapidly generalizes druggability strategies to similar PPI families, achieving efficient matrix-like expansion of high-barrier pipelines.